These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 37315680)

  • 1. A nanobody-based complement inhibitor targeting complement component 2 reduces hemolysis in a complement humanized mouse model of autoimmune hemolytic anemia.
    Chen JY; Zhang L; Luo L; Yang M; Chen Y; Lin F
    Clin Immunol; 2023 Aug; 253():109678. PubMed ID: 37315680
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ARGX-117, a therapeutic complement inhibiting antibody targeting C2.
    Van de Walle I; Silence K; Budding K; Van de Ven L; Dijkxhoorn K; de Zeeuw E; Yildiz C; Gabriels S; Percier JM; Wildemann J; Meeldijk J; Simons PJ; Boon L; Cox L; Holgate R; Urbanus R; Otten HG; Leusen JHW; Blanchetot C; de Haard H; Hack CE; Boross P
    J Allergy Clin Immunol; 2021 Apr; 147(4):1420-1429.e7. PubMed ID: 32926878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An Ultrahigh-Affinity Complement C4b-Specific Nanobody Inhibits In Vivo Assembly of the Classical Pathway Proconvertase.
    Zarantonello A; Presumey J; Simoni L; Yalcin E; Fox R; Hansen A; Olesen HG; Thiel S; Johnson MB; Stevens B; Laursen NS; Carroll MC; Andersen GR
    J Immunol; 2020 Sep; 205(6):1678-1694. PubMed ID: 32769120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Classical complement activation on human erythrocytes in subjects with systemic lupus erythematosus and a history of autoimmune hemolytic anemia.
    Hair P; Goldman DW; Li J; Petri M; Krishna N; Cunnion K
    Lupus; 2020 Sep; 29(10):1179-1188. PubMed ID: 32659155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complement inhibitors to treat IgM-mediated autoimmune hemolysis.
    Wouters D; Zeerleder S
    Haematologica; 2015 Nov; 100(11):1388-95. PubMed ID: 26521297
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of complement activation by recombinant Sh-CRIT-ed1 analogues.
    Oh KS; Kweon MH; Rhee KH; Ho Lee K; Sung HC
    Immunology; 2003 Sep; 110(1):73-9. PubMed ID: 12941143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of iodine and thiol-blocking reagents on complement component C2 and on the assembly of the classical-pathway C3 convertase.
    Kerr MA; Parkes C
    Biochem J; 1984 Apr; 219(2):391-9. PubMed ID: 6611150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complement Activation and Inhibition in Autoimmune Hemolytic Anemia: Focus on Cold Agglutinin Disease.
    Berentsen S
    Semin Hematol; 2018 Jul; 55(3):141-149. PubMed ID: 30032751
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complement C2 receptor inhibitor trispanning and the beta-chain of C4 share a binding site for complement C2.
    Inal JM; Schifferli JA
    J Immunol; 2002 May; 168(10):5213-21. PubMed ID: 11994478
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular pharmacology in complement-mediated hemolytic disorders.
    Bortolotti M; Barcellini W; Fattizzo B
    Eur J Haematol; 2023 Sep; 111(3):326-336. PubMed ID: 37308291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence for a C4b binding site on the C2b domain of C2.
    Oglesby TJ; Accavitti MA; Volanakis JE
    J Immunol; 1988 Aug; 141(3):926-31. PubMed ID: 3397535
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complement component C2, inhibiting a latent serine protease in the classical pathway of complement activation.
    Halili MA; Ruiz-Gómez G; Le GT; Abbenante G; Fairlie DP
    Biochemistry; 2009 Sep; 48(35):8466-72. PubMed ID: 19642650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Surface modulation of classical pathway activation: C2 and C3 convertase formation and regulation on sheep, guinea pig, and human erythrocytes.
    Brown EJ; Ramsey J; Hammer CH; Frank MM
    J Immunol; 1983 Jul; 131(1):403-8. PubMed ID: 6602833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Formation of classical C3 convertase during the alternative pathway of human complement activation].
    Kozlov LV; Shibanova ED; Zinchenko AA
    Biokhimiia; 1987 Apr; 52(4):660-6. PubMed ID: 3647798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The mechanism of action of decay-accelerating factor (DAF). DAF inhibits the assembly of C3 convertases by dissociating C2a and Bb.
    Fujita T; Inoue T; Ogawa K; Iida K; Tamura N
    J Exp Med; 1987 Nov; 166(5):1221-8. PubMed ID: 2445886
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-C1s humanized monoclonal antibody SAR445088: A classical pathway complement inhibitor specific for the active form of C1s.
    Simmons KT; Chan J; Hussain S; Rose EL; Markham K; Byun TS; Panicker S; Parry GC; Storek M
    Clin Immunol; 2023 Jun; 251():109629. PubMed ID: 37149117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Features of serum complement C3 and C4 levels in autoimmune hemolytic anemia patients.
    Wang Z; Bo L; Xu Y; Liu H; Zhao Y
    Int J Lab Hematol; 2021 Oct; 43(5):1154-1158. PubMed ID: 33459487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanism of action of the C4 nephritic factor. Deregulation of the classical pathway of C3 convertase.
    Gigli I; Sorvillo J; Mecarelli-Halbwachs L; Leibowitch J
    J Exp Med; 1981 Jul; 154(1):1-12. PubMed ID: 7019379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular interactions between MASP-2, C4, and C2 and their activation fragments leading to complement activation via the lectin pathway.
    Wallis R; Dodds AW; Mitchell DA; Sim RB; Reid KB; Schwaeble WJ
    J Biol Chem; 2007 Mar; 282(11):7844-51. PubMed ID: 17204478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sutimlimab: First Approval.
    Dhillon S
    Drugs; 2022 May; 82(7):817-823. PubMed ID: 35412113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.